Literature DB >> 19748926

Involvement of p29 in DNA damage responses and Fanconi anemia pathway.

Po-Chen Chu1, Tao-Yeuan Wang, Yen-Ta Lu, Chuan-Kai Chou, Yuh-Cheng Yang, Mau-Sun Chang.   

Abstract

Human p29 is a chromatin-associated protein and the silencing of p29 expression increases cell population in G(1) phase and decreases phosphorylation levels of Chk1 and Chk2 in response to UV treatment. To further characterize the function of p29, U2OS and Fanconi anemia complementation group G (FA-G) cells with constitutive p29 expression have been established. Analyses of these cells identified increased phosphorylation levels of Chk1 and Chk2, which were accompanied by elevated amounts of chromatin-associated Mre11-Rad50-Nbs1 complex and ATR-IP. Monoubiquitination of the FA ID complex was restored in p29 stably expressing FA-G cells. Moreover, lower tumor incidence was observed in mp29 transgenic mice after UV irradiation. These results suggest the involvement of p29 in the DNA damage responses and Fanconi anemia pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748926     DOI: 10.1093/carcin/bgp204

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

1.  SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation.

Authors:  Sujuan Yan; Yan Deng; Yong Qiang; Qinghua Xi; Rong Liu; Shuyun Yang; Jian Liu; Chunhui Tang; Jianxin Zhong; Yingying Wang
Journal:  Tumour Biol       Date:  2015-01-28

2.  Knocking down the expression of SYF2 inhibits the proliferation of glioma cells.

Authors:  Jun Guo; Lixiang Yang; Jianfeng Huang; Xiancheng Liu; Xiaojun Qiu; Tao Tao; Yonghua Liu; Xiaojuan He; Na Ban; Shaochen Fan; Guan Sun
Journal:  Med Oncol       Date:  2014-07-02       Impact factor: 3.064

3.  Upregulation of SYF2 in esophageal squamous cell carcinoma promotes tumor cell proliferation and predicts poor prognosis.

Authors:  Junya Zhu; Lili Ji; Jianguo Zhang; Lei Yang; Chengqi Guan; Yayun Wang; Jia Zhu; Li Liang; Runzhou Ni
Journal:  Tumour Biol       Date:  2014-07-18

4.  Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.

Authors:  Shusen Zhang; Weidong Shi; Yuyan Chen; Zhiwei Xu; Jia Zhu; Tingting Zhang; Wei Huang; Runzhou Ni; Cuihua Lu; Xiubing Zhang
Journal:  Mol Cell Biochem       Date:  2015-08-11       Impact factor: 3.396

5.  Genome-wide identification and functional analysis of the splicing component SYF2/NTC31/p29 across different plant species.

Authors:  Yuan Tian; Mo-Xian Chen; Jing-Fang Yang; H H K Achala; Bei Gao; Ge-Fei Hao; Guang-Fu Yang; Zhi-Yong Dian; Qi-Juan Hu; Di Zhang; Jianhua Zhang; Ying-Gao Liu
Journal:  Planta       Date:  2018-10-13       Impact factor: 4.116

6.  Disruption of murine mp29/Syf2/Ntc31 gene results in embryonic lethality with aberrant checkpoint response.

Authors:  Chia-Hsin Chen; Po-Chen Chu; Liekyeow Lee; Huang-Wei Lien; Tse-Ling Lin; Chi-Chen Fan; Peter Chi; Chang-Jen Huang; Mau-Sun Chang
Journal:  PLoS One       Date:  2012-03-20       Impact factor: 3.240

7.  Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer.

Authors:  Feng Shi; Feng-Feng Cai; Lu Cai; Xiao-Yan Lin; Wei Zhang; Qin-Qin Wang; Yu-Jie Zhao; Qi-Chao Ni; Hua Wang; Zhi-Xian He
Journal:  Oncotarget       Date:  2017-05-23

8.  ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin.

Authors:  Iris Tanaka; Alina Chakraborty; Olivier Saulnier; Clara Benoit-Pilven; Sophie Vacher; Dalila Labiod; Eric W F Lam; Ivan Bièche; Olivier Delattre; Frédéric Pouzoulet; Didier Auboeuf; Stéphan Vagner; Martin Dutertre
Journal:  Nucleic Acids Res       Date:  2020-03-18       Impact factor: 16.971

9.  BCAS2, a protein enriched in advanced prostate cancer, interacts with NBS1 to enhance DNA double-strand break repair.

Authors:  Hsiang-Po Huang; Show-Li Chen; Li-Po Wang; Tzu-Yu Chen; Chun-Kai Kang
Journal:  Br J Cancer       Date:  2020-09-23       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.